Literature DB >> 10733339

Promotion of chondrocyte proliferation by versican mediated by G1 domain and EGF-like motifs.

Y Zhang1, L Cao, C Kiani, B L Yang, W Hu, B B Yang.   

Abstract

We have previously demonstrated that versican stimulated NIH3T3 fibroblast proliferation. Since versican is expressed in cartilage, we investigated whether versican plays a role in chondrocyte proliferation. We developed a technique to stably express a recombinant versican mini-gene in chicken chondrocytes, and its effect on chondrocyte proliferation was analyzed by the increase in cell number. The effect of cell adhesion on cell proliferation was tested. Finally, the versican mini-gene was truncated to assess the role of EGF-like motifs in cell proliferation. Expression of the recombinant versican mini-gene stimulated chondrocyte proliferation. Antisense oligonucleotides complementary to versican inhibited chondrocyte proliferation. The G1 domain of versican stimulated chondrocyte proliferation by destabilizing chondrocyte adhesion. Furthermore, deletion of the two EGF-like motifs from the G3 domain also reduced the function of versican in stimulating cell proliferation. Versican enhances chondrocyte proliferation through a mechanism involving its G1 and G3 domains. This finding may have implications for our understanding of the pathogenesis of various joint diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10733339

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  23 in total

1.  V3 versican isoform alters the behavior of human melanoma cells by interfering with CD44/ErbB-dependent signaling.

Authors:  Daniel Hernández; Laia Miquel-Serra; María-José Docampo; Anna Marco-Ramell; Jennifer Cabrera; Angels Fabra; Anna Bassols
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

2.  Potential of exogenous cartilage proteoglycan as a new material for cartilage regeneration.

Authors:  Shusa Ohshika; Yasuyuki Ishibashi; Atsushi Kon; Tomomi Kusumi; Hiroshi Kijima; Satoshi Toh
Journal:  Int Orthop       Date:  2011-08-12       Impact factor: 3.075

3.  Proteolytic cleavage of versican during cardiac cushion morphogenesis.

Authors:  Christine B Kern; Waleed O Twal; Corey H Mjaatvedt; Sarah E Fairey; Bryan P Toole; M Luisa Iruela-Arispe; W Scott Argraves
Journal:  Dev Dyn       Date:  2006-08       Impact factor: 3.780

4.  Versican proteolysis mediates myocardial regression during outflow tract development.

Authors:  Christine B Kern; Russell A Norris; Robert P Thompson; W Scott Argraves; Sarah E Fairey; Leticia Reyes; Stanley Hoffman; Roger R Markwald; Corey H Mjaatvedt
Journal:  Dev Dyn       Date:  2007-03       Impact factor: 3.780

Review 5.  The different roles of aggrecan interaction domains.

Authors:  Anders Aspberg
Journal:  J Histochem Cytochem       Date:  2012-09-26       Impact factor: 2.479

6.  The roles of microRNAs in tumorigenesis and angiogenesis.

Authors:  Weining Yang; Daniel Y Lee; Yaacov Ben-David
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2010-06-18

Review 7.  Versican and the regulation of cell phenotype in disease.

Authors:  Thomas N Wight; Michael G Kinsella; Stephen P Evanko; Susan Potter-Perigo; Mervyn J Merrilees
Journal:  Biochim Biophys Acta       Date:  2014-01-05

Review 8.  The multiple, complex roles of versican and its proteolytic turnover by ADAMTS proteases during embryogenesis.

Authors:  Sumeda Nandadasa; Simon Foulcer; Suneel S Apte
Journal:  Matrix Biol       Date:  2014-01-18       Impact factor: 11.583

Review 9.  Versican degradation and vascular disease.

Authors:  Richard D Kenagy; Anna H Plaas; Thomas N Wight
Journal:  Trends Cardiovasc Med       Date:  2006-08       Impact factor: 6.677

10.  Reduced versican cleavage due to Adamts9 haploinsufficiency is associated with cardiac and aortic anomalies.

Authors:  Christine B Kern; Andy Wessels; Jessica McGarity; Laura J Dixon; Ebony Alston; W Scott Argraves; Danielle Geeting; Courtney M Nelson; Donald R Menick; Suneel S Apte
Journal:  Matrix Biol       Date:  2010-01-22       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.